| Khwaja A Ahmed, MD | |
|
145 Innovation Dr, Jackson, TN 38305-3019 | |
| (731) 422-0213 | |
| (731) 422-0297 |
| Full Name | Khwaja A Ahmed |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 27 Years |
| Location | 145 Innovation Dr, Jackson, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982623864 | NPI | - | NPPES |
| 3000038 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 41816 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jackson-madison County General Hospital | Jackson, TN | Hospital |
| Baptist Memorial Hospital - Carroll County | Huntingdon, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Jackson Clinic Pa | 2668376872 | 176 |
News Archive
In a recent bioRxiv paper, researchers from Norway and the US demonstrate the presence of a highly conserved, mobile genetic element (thus far with unknown function) in genomes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a large number of insects – opening the door for hitherto unexplored treatment opportunities.
Burkitt lymphoma (BL) is a highly aggressive form of non-Hodgkin lymphoma (NHL) that comes in three different variants: endemic, immunodeficiency-associated, and sporadic. Of these variants, sporadic BL is most commonly found outside malaria-endemic countries and typically seen in young adults.
Continuous glucose monitoring (CGM) tracks glucose levels of people with type I or type II diabetes through a device that monitors levels throughout the day.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
Dr. Richard Dolinar, chairman of the Alliance for Safe Biologic Medicines (Alliance) outlined five areas of concern that the U.S. Food and Drug Administration (FDA) should resolve before they allow biosimilar medications on the U.S. drug market in prepared testimony for the FDA's May 11th public hearing. The event addressed the FDA's recent draft guidelines for the development of biosimilar products.
› Verified 7 days ago
| Entity Name | Jackson Clinic Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285629386 PECOS PAC ID: 2668376872 Enrollment ID: O20040318000962 |
News Archive
In a recent bioRxiv paper, researchers from Norway and the US demonstrate the presence of a highly conserved, mobile genetic element (thus far with unknown function) in genomes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a large number of insects – opening the door for hitherto unexplored treatment opportunities.
Burkitt lymphoma (BL) is a highly aggressive form of non-Hodgkin lymphoma (NHL) that comes in three different variants: endemic, immunodeficiency-associated, and sporadic. Of these variants, sporadic BL is most commonly found outside malaria-endemic countries and typically seen in young adults.
Continuous glucose monitoring (CGM) tracks glucose levels of people with type I or type II diabetes through a device that monitors levels throughout the day.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
Dr. Richard Dolinar, chairman of the Alliance for Safe Biologic Medicines (Alliance) outlined five areas of concern that the U.S. Food and Drug Administration (FDA) should resolve before they allow biosimilar medications on the U.S. drug market in prepared testimony for the FDA's May 11th public hearing. The event addressed the FDA's recent draft guidelines for the development of biosimilar products.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Khwaja A Ahmed, MD Po Box 400, Jackson, TN 38302-0400 Ph: (731) 425-5752 | Khwaja A Ahmed, MD 145 Innovation Dr, Jackson, TN 38305-3019 Ph: (731) 422-0213 |
News Archive
In a recent bioRxiv paper, researchers from Norway and the US demonstrate the presence of a highly conserved, mobile genetic element (thus far with unknown function) in genomes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a large number of insects – opening the door for hitherto unexplored treatment opportunities.
Burkitt lymphoma (BL) is a highly aggressive form of non-Hodgkin lymphoma (NHL) that comes in three different variants: endemic, immunodeficiency-associated, and sporadic. Of these variants, sporadic BL is most commonly found outside malaria-endemic countries and typically seen in young adults.
Continuous glucose monitoring (CGM) tracks glucose levels of people with type I or type II diabetes through a device that monitors levels throughout the day.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
Dr. Richard Dolinar, chairman of the Alliance for Safe Biologic Medicines (Alliance) outlined five areas of concern that the U.S. Food and Drug Administration (FDA) should resolve before they allow biosimilar medications on the U.S. drug market in prepared testimony for the FDA's May 11th public hearing. The event addressed the FDA's recent draft guidelines for the development of biosimilar products.
› Verified 7 days ago
William A Preston, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 700 W Forest Ave, Ste 300, Jackson, TN 38301 Phone: 731-422-0340 Fax: 731-422-0297 | |
Dr. Karl Eric Studtmann, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 619 Skyline Dr, Jackson, TN 38301 Phone: 731-424-3682 Fax: 731-423-2714 | |
Dr. William Keith Wainscott, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 619 Skyline Dr, Jackson, TN 38301 Phone: 731-424-3682 Fax: 731-423-2714 | |
Dr. Robert Douglas Fowler, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 145 Innovation Dr, Jackson, TN 38305 Phone: 731-422-0213 Fax: 731-422-0297 | |
Ronald H Kirkland, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 700 W Forest Ave, Ste 300, Jackson, TN 38301 Phone: 731-422-0340 Fax: 731-422-0297 |